Contract Pharma Manufacturing News

  1. OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval For Generic Semaglutide Injection 4/29/2026

    OneSource Specialty Pharma Limited today announced that its partner Dr. Reddy’s Laboratories Ltd., has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.

  2. Porton Advanced And Dark Horse Consulting Group Announce Memorandum Of Understanding Providing A Streamlined Path To Conducting IITs In China 4/29/2026

    Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally.

  3. Genezen And The Charlotte & Gwenyth Gray Foundation To Cure Batten Disease Announce Manufacturing Partnership For CLN6 Gene Therapy Clinical Trial 4/28/2026

    Genezen, a gene therapy contract development and manufacturing organization (CDMO), and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease today announced a manufacturing partnership to advance a CLN6 gene therapy into a Phase 1/2 clinical trial.

  4. Emergent BioSolutions And Substipharm Biologics Announce Strategic Manufacturing Partnership To Support Japanese Encephalitis Vaccine In The United States 4/28/2026

    Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent’s Canton, Massachusetts facility, and for Emergent to serve as the exclusive distributor of the vaccine to the U.S. government, following potential U.S. Food & Drug Administration (FDA) regulatory endeavors.

  5. CellProthera Collaborates With Quintessence Biotech To Industrialize Cell Manufacturing Processes Ahead Of Stroke Clinical Trials 4/28/2026

    CellProthera announces a new collaboration to optimize manufacturing processes using Quintessence’s technology, preparing its cell therapy to advance into clinical trials for the treatment of ischemic stroke.

  6. AGC Biologics Wins 2026 Fierce Outsourcing Award For Leadership In Regulatory And Quality Compliance 4/27/2026

    AGC Biologics, your friendly CDMO expert, is the 2026 recipient of the Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance.

  7. AbbVie Announces $1.4 Billion North Carolina Campus To Expand U.S. Pharmaceutical Manufacturing Capacity 4/27/2026

    AbbVie today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.

  8. Xcovery Partners With EVERSANA To Commercialize Lung Cancer Drug Ensacove In The U.S. 4/27/2026

    Xcovery Holdings, Inc., (Xcovery) an evidence-based, innovation-driven pharmaceutical company, today announced an agreement with EVERSANA®, a leading provider of commercialization services to the global life sciences industry, to support and expand the U.S. commercial launch of ENSACOVE™ (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

  9. Backed By Investments Exceeding $1B, PCI Pharma Services Announces Major Expansion Of US Sterile Fill-Finish And Drug-Device Delivery Combination Capabilities 4/27/2026

    PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities.

  10. Dark Horse Consulting Group And Porton Advanced Announce Memorandum Of Understanding Providing A Streamlined Path To Conducting IITs In China 4/26/2026

    Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally.